Peptide Comparison
MK-677 vs Hulk Stack
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
MK-677 has stronger documented evidence (Phase 3 (not approved)) than Hulk Stack (Anecdotal) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| MK-677 | Hulk Stack | |
|---|---|---|
| Class | Oral non-peptide ghrelin receptor agonist | GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine | Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. |
| Route | Oral | SC injection (typically 2-3 separate sites) |
| Half-life | ~24 hrs | CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs |
| Dosage (research) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) | Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks |
| Evidence tier | Phase 3 (not approved) | Anecdotal |
| Research depth | 120 indexed | — |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) | Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MK-677 or Hulk Stack?
MK-677 has stronger documented evidence (Phase 3 (not approved)) than Hulk Stack (Anecdotal) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between MK-677 and Hulk Stack?
MK-677 is classed as Oral non-peptide ghrelin receptor agonist; Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: MK-677, ~24 hrs; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: MK-677, Oral; Hulk Stack, SC injection (typically 2-3 separate sites).
Which has stronger evidence, MK-677 or Hulk Stack?
MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.
Which is more accessible, MK-677 or Hulk Stack?
Neither MK-677 nor Hulk Stack is an FDA-approved drug. Catalog status: MK-677, Research Chemical; Hulk Stack, Compounding Restricted. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).
Are MK-677 and Hulk Stack ever combined?
MK-677 and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…